- Noteworthy events during the week of October 6 - 12 for healthcare investors.
- MONDAY (10/7): Alnylam Pharmaceuticals (NASDAQ:ALNY): Roundtable webcast - givosiran for acute hepatic porphyria.
- Summit Therapeutics (NASDAQ:SMMT): R&D Day, NYC.
- WEDNESDAY (10/9): European Academy of Dermatology and Venereology Congress, Madrid (5 days). XBiotech (NASDAQ:XBIT): Phase 2 data on bermekimab in atopic dermatitis.
- THURSDAY (10/10): Alnylam Pharmaceuticals: Roundtable webcast: lumasiran for primary hyperoxaluria type 1.
- SATURDAY (10/12): American Academy of Ophthalmology Annual Meeting, San Francisco (4 days). REGENXBIO (NASDAQ:RGNX): Phase 1/2a data on RGX-314 in wet AMD. Adverum Biotechnologies (NASDAQ:ADVM): Phase 1 24-week data on ADVM-022 in wet AMD. MeiraGTx Holdings (NASDAQ:MGTX): Phase 1/2 data on AAV-RPE65 in retinal dystrophy. Aldeyra Therapeutics (NASDAQ:ALDX): Data from Phase 3 ALLEVIATE study of reproxalap in allergic conjunctivitis. Kodiak Sciences (NASDAQ:KOD): Phase 1b data on KSI-301 in treatment-naive wet AMD.